+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Oncology Drugs Market Research Reports

T Cell Surface Glycoprotein CD3 Epsilon Chain Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

T Cell Surface Glycoprotein CD3 Epsilon Chain Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 43 Pages
  • Global
From
T Cell Surface Glycoprotein CD4 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

T Cell Surface Glycoprotein CD4 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 49 Pages
  • Global
From
Cells Expressing T Cell Surface Glycoprotein CD4 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Cells Expressing T Cell Surface Glycoprotein CD4 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 35 Pages
  • Global
From
Peripheral T-Cell Lymphomas Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Peripheral T-Cell Lymphomas Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 165 Pages
  • Global
From
Transforming Growth Factor Beta 1 (TGFB1) Drugs In Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Transforming Growth Factor Beta 1 (TGFB1) Drugs In Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • February 2022
  • 112 Pages
  • Global
From
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) Drugs In Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) Drugs In Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • February 2022
  • 62 Pages
  • Global
From
Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) Drugs In Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) Drugs In Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • February 2022
  • 42 Pages
  • Global
From
Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) Drugs In Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) Drugs In Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • February 2022
  • 44 Pages
  • Global
From
Smoothened Homolog (Protein Gx or SMO) - Drugs In Development, 2021 - Product Thumbnail Image

Smoothened Homolog (Protein Gx or SMO) - Drugs In Development, 2021

  • Report
  • December 2021
  • 91 Pages
  • Global
From
Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) - Drugs in Development, 2021 - Product Thumbnail Image

Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) - Drugs in Development, 2021

  • Drug Pipelines
  • March 2021
  • Global
From
Melanoma - Pipeline Review, H2 2020 - Product Thumbnail Image

Melanoma - Pipeline Review, H2 2020

  • Drug Pipelines
  • November 2020
  • 3809 Pages
  • Global
From
Vaginal Cancer - Pipeline Review, H2 2020 - Product Thumbnail Image

Vaginal Cancer - Pipeline Review, H2 2020

  • Drug Pipelines
  • November 2020
  • 475 Pages
  • Global
From
Retinoblastoma - Pipeline Review, H2 2020 - Product Thumbnail Image

Retinoblastoma - Pipeline Review, H2 2020

  • Drug Pipelines
  • October 2020
  • 72 Pages
  • Global
From
Head And Neck Cancer - Pipeline Review, H2 2020 - Product Thumbnail Image

Head And Neck Cancer - Pipeline Review, H2 2020

  • Drug Pipelines
  • October 2020
  • 3419 Pages
  • Global
From
Gastric Cancer - Pipeline Review, H2 2020 - Product Thumbnail Image

Gastric Cancer - Pipeline Review, H2 2020

  • Drug Pipelines
  • October 2020
  • 2657 Pages
  • Global
From
Pancreatic Cancer - Pipeline Review, H2 2020 - Product Thumbnail Image

Pancreatic Cancer - Pipeline Review, H2 2020

  • Drug Pipelines
  • September 2020
  • 4317 Pages
  • Global
From
Chemotherapy Induced Neutropenia - Pipeline Review, H2 2020 - Product Thumbnail Image

Chemotherapy Induced Neutropenia - Pipeline Review, H2 2020

  • Drug Pipelines
  • July 2020
  • 152 Pages
  • Global
From
Myelodysplastic Syndrome - Pipeline Review, H1 2020 - Product Thumbnail Image

Myelodysplastic Syndrome - Pipeline Review, H1 2020

  • Drug Pipelines
  • June 2020
  • 1667 Pages
  • Global
From
CD40 Ligand - Pipeline Review, H2 2019 - Product Thumbnail Image

CD40 Ligand - Pipeline Review, H2 2019

  • Drug Pipelines
  • December 2019
  • 74 Pages
  • Global
From
Cancer Testis Antigen 1 - Pipeline Review, H2 2019 - Product Thumbnail Image

Cancer Testis Antigen 1 - Pipeline Review, H2 2019

  • Drug Pipelines
  • December 2019
  • 76 Pages
  • Global
From
Loading Indicator

The Oncology Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat cancer. These drugs are used to treat a variety of cancers, including breast, lung, and prostate cancer. Oncology drugs are typically administered intravenously or orally, and can be used in combination with other treatments such as radiation and chemotherapy. The Oncology Drugs market is highly competitive, with many large pharmaceutical companies vying for market share. Some of the major players in the market include Bristol-Myers Squibb, Merck & Co., Pfizer, Novartis, and Roche. These companies are constantly researching and developing new drugs to treat cancer, as well as improving existing treatments. Additionally, many smaller companies are also involved in the Oncology Drugs market, providing innovative treatments and therapies. Show Less Read more